Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleClinical Investigations

Tyrosine Kinase Inhibitor Sorafenib Decreases 111In-Girentuximab Uptake in Patients with Clear Cell Renal Cell Carcinoma

Constantijn H.J. Muselaers, Alexander B. Stillebroer, Ingrid M.E. Desar, Marye J. Boers-Sonderen, Carla M.L. van Herpen, Mirjam C.A. de Weijert, Johan F. Langenhuijsen, Egbert Oosterwijk, William P.J. Leenders, Otto C. Boerman, Peter F.A. Mulders and Wim J.G. Oyen
Journal of Nuclear Medicine February 2014, 55 (2) 242-247; DOI: https://doi.org/10.2967/jnumed.113.131110
Constantijn H.J. Muselaers
1Radboud university medical center, Department of Urology, Nijmegen, The Netherlands
2Radboud university medical center, Department of Nuclear Medicine, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander B. Stillebroer
1Radboud university medical center, Department of Urology, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ingrid M.E. Desar
3Radboud university medical center, Department of Medical Oncology, Nijmegen, The Netherlands; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marye J. Boers-Sonderen
3Radboud university medical center, Department of Medical Oncology, Nijmegen, The Netherlands; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carla M.L. van Herpen
3Radboud university medical center, Department of Medical Oncology, Nijmegen, The Netherlands; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mirjam C.A. de Weijert
1Radboud university medical center, Department of Urology, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johan F. Langenhuijsen
1Radboud university medical center, Department of Urology, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Egbert Oosterwijk
1Radboud university medical center, Department of Urology, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William P.J. Leenders
4Radboud university medical center, Department of Pathology, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Otto C. Boerman
2Radboud university medical center, Department of Nuclear Medicine, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter F.A. Mulders
1Radboud university medical center, Department of Urology, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wim J.G. Oyen
2Radboud university medical center, Department of Nuclear Medicine, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Abstract

Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of metastatic clear cell renal cell carcinoma (RCC). Although TKIs have demonstrated good clinical efficacy, the lack of complete responses, the chronic nature of the treatment, and the side effects are clear disadvantages. An interesting new approach in the treatment of clear cell RCC is antibody-mediated therapy with the chimeric anti–carbonic anhydrase IX (CAIX) antibody girentuximab (cG250). As the results of several girentuximab trials become available, the question arises of whether TKI treatment can be combined with girentuximab-based therapy. In this study, we assessed the effect of the widely used TKI sorafenib on the tumor-targeting potential of 111In-labeled girentuximab. Methods: 111In-girentuximab imaging was performed on 15 patients suspected of having a renal malignancy, with surgery being part of their treatment plan. Of these, 10 patients were treated in a neoadjuvant setting with sorafenib (400 mg orally twice daily). Five patients received treatment during 1 wk, and 5 patients received treatment during 4 wk. In both sorafenib-treated groups, baseline and posttreatment tumor targeting of 111In-girentuximab were compared. Surgery was performed 3 d after the last image acquisition. Five additional patients were included as a control group and had only a single 111In-girentuximab injection and scintigraphy without any treatment. Distribution of 111In-girentuximab was determined scintigraphically ex vivo in a 1-cm lamella of the resected tumorous kidney. Expression of CAIX and of the vascular marker CD31 was determined immunohistochemically on specimens of both tumor and normal kidney tissue. Results: Treatment with sorafenib resulted in a marked decrease of 111In-girentuximab uptake in the tumor in clear cell RCC patients, especially in the group treated for 4 wk (mean change in both sorafenib-treated groups, −38.4%; range, +9.1% to −79.4%). Immunohistochemical analysis showed markedly reduced CD31 expression and vessel density in the sorafenib-treated groups but no differences in CAIX expression between the sorafenib-treated groups and the nontreated patients. Conclusion: Treatment with sorafenib resulted in a treatment duration–dependent significantly decreased uptake of 111In-girentumab in clear cell RCC lesions. These results indicate that the efficacy of antibody-mediated treatment or diagnosis modalities is hampered by TKI treatment.

  • CAIX
  • girentuximab
  • imaging
  • renal cell carcinoma
  • tyrosine kinase inhibitor

Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of renal cell carcinoma (RCC) during the last 5 y. Sunitinib, sorafenib, and pazopanib are now standard care in patients with advanced disease (1–3). Although excellent results for progression-free survival have been achieved, there are limitations to the use of TKIs. First, these agents have a cytostatic rather than cytotoxic effect, and thus complete responses are rarely seen. Second, severe side effects such as hypertension, nausea, hand–foot skin reactions, and diarrhea can occur, and sustained low-grade toxicity can lead to dose adjustments. Third, the long-term effects of these agents are largely unknown (4). Moreover, TKI treatment is chronic, and cessation of treatment may lead to flare-up of the disease, possibly due to rapid neovascularization (5). A new alternative approach in the treatment of clear cell RCC is antibody-mediated therapy using the chimeric anti–carbonic anhydrase IX (CAIX) antibody girentuximab (cG250). CAIX is an antigen ubiquitously expressed in clear cell RCC (6,7), but expression in normal tissues is low or absent (8). The high and specific expression in clear cell RCC makes CAIX an excellent target for antibody-mediated therapy. Girentuximab has been studied in radioimmunotherapy trials in patients with metastatic disease (9–15) and is currently studied in trials in an adjuvant setting (ARISER, or Adjuvant RENCAREX [Wilex AG] Immunotherapy Trial to Study Efficacy in Nonmetastasised Renal Cell Carcinoma) (16). Because we recently published promising results for the most recent therapy trial (15), the question arises of whether antibody-mediated treatment can be combined with TKI treatment.

In this trial, we aimed to determine the effect of the widely used TKI sorafenib on tumor targeting of 111In-labeled chimeric anti-CAIX monoclonal antibody girentuximab in preoperative patients presenting with a renal mass suspected of being RCC. To assess the effect of the duration of the treatment, patients were treated either during 1 wk or during 4 wk.

MATERIALS AND METHODS

Study Design

Fifteen patients with renal masses suspected of being RCC and for whom surgery was planned were included in this study.

Before inclusion at baseline (day −14 to day 0), a physical examination (including vital signs and weight) was performed, biochemical laboratory parameters were assessed, and a resting electrocardiogram was made. The study was approved by the institutional review board (CMO Arnhem-Nijmegen). Written informed consent was obtained from every patient. This trial is registered on www.clinicaltrials.gov, number NCT00602862.

Two groups of 5 patients were infused with 111In-labeled girentuximab (100 MBq; 5 mg), and whole-body and SPECT images were obtained 7 d later. Imaging was followed by treatment with sorafenib (Nexavar [Bayer], 400 mg twice a day orally) for 1 wk or 4 wk (Fig. 1). All sorafenib-treated patients underwent a second injection with 111In-girentuximab and imaging 7 d after injection. The sorafenib treatment was discontinued on the day of the last scan in both groups. Five patients served as a control group and received a single infusion of 111In-girentuximab 10 d before nephrectomy and were scanned 7 d later but did not receive sorafenib treatment. The study design is summarized in Figure 1.

FIGURE 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1.

Study design.

Study Drugs

Sorafenib was administered orally in a dosage of 400 mg twice a day. Dose interruptions and reductions were allowed when there were adverse events of grade III or higher according to the Common Terminology Criteria for Adverse Events, version 3.0 (National Cancer Institute).

For scintigraphic imaging, diethylenetriaminepentaacetic acid (DTPA) was conjugated to girentuximab (cG250; Wilex AG) at pH 9.5. A 50-fold molar excess of isothiocyanato-benzyl-DTPA was used to obtain a molar substitution ratio of 0.5–2.0. After conjugation, the unconjugated DTPA was removed by extensive dialysis against a 0.25 M ammonium acetate buffer, pH 5.4. Aliquots of the girentuximab-DTPA solution were placed into sterile vials (5 mg in 1.0 mL) and stored at −20°C until use. This procedure has been previously described in more detail (14). After inclusion of a patient, the girentuximab-DTPA conjugate was labeled with 100 MBq of 111In (Covidien). The volume of 111In-DTPA-girentuximab was adjusted to 10 mL with NaCl, 0.9%.

Radiochemical purity was determined by instant thin-layer chromatography. All preparations used in this study exceeded 95%.

Imaging and Quantitative Image Analysis

On the basis of previous studies, whole-body scans were acquired 7 d after injection using a double-head γ camera (E.cam; Siemens Inc.) equipped with parallel-hole medium-energy collimators (symmetric 15% window over 172 and 247 keV) and a scan speed of 4 cm/min (17). The sorafenib-treated groups were injected and scanned twice; the same imaging procedures were used for both scans.

In the group that was treated with sorafenib for 1 wk, 111In-girentuximab was administered at 11 d before the start of sorafenib treatment and on the day that treatment began. Treatment with sorafenib was started 4 d after the first 111In-girentuximab image was acquired. Each time, scintigraphic imaging was performed 7 d after injection of 111In-girentuximab (Fig. 1).

In the group that received 4 wk of sorafenib, 111In-girentuximab was administered at 7 d before the start of sorafenib treatment and after 21 d of treatment, each time followed by scintigraphy 7 d after injection. The sorafenib treatment was stopped in both groups on the day of the last scan, and 3 d later a (partial) tumor nephrectomy was performed (Fig. 1).

In the control group, patients were intravenously infused with 111In-girentuximab 10 d before nephrectomy and scanned 7 d after injection of the radiolabeled antibody.

Whole-body planar images were analyzed quantitatively, as described by Visser et al. (18). Regions of interest were drawn around tumors and normal kidney. Targeting was expressed as the percentage injected dose per tissue weight (%ID/g), assuming a tissue density of 1.0 g/mL. Tumor volumes were determined using Inveon Research Workplace software (Siemens Inc.).

Processing of the Surgical Specimen

After nephrectomy, a 1-cm-thick slice of the resected tissue containing both tumor and normal tissue was scanned on the γ camera, using only a single detector. After imaging, the slice was cut into 1-cm3 blocks. Tissue blocks were weighed, and radioactivity in each sample was determined in a well-type γ counter (1480 Wizard; LKB/Wallace, Perkin-Elmer). After quantitative analysis, the tissue blocks were processed for immunohistochemical analysis.

Immunohistochemical Analysis

CAIX expression was detected by staining with anti-CAIX mouse monoclonal antibody M75, a hybridoma supernatant obtained from the HB-11128 ATCC cell line. CD31 staining was performed with murine anti-CD31 monoclonal antibody JC70A (Dako). After staining, expression of CAIX and CD31 was scored by 4 independent observers on a scale ranging from undetectable (−) to low (±), moderate (+), high (++), and very high (+++).

Statistics

A nonparametric Wilcoxon signed-ranked test was performed to assess the change in 111In-girentuximab uptake in the tumor before and after sorafenib treatment. A P value of less than 0.05 was considered significant.

RESULTS

Patients

Patient characteristics are summarized in Table 1. Ten patients were treated with sorafenib (7 women and 3 men; median age, 62.4 y; range, 50.2–74.4 y). The tumors of 9 of these patients were clear cell RCC as determined by pathology (patients 2, 3, 4, 5, 7, and 9) or contained a clear cell RCC component (patients 1, 6, and 8). Patient 1 had a poorly differentiated tumor, partly clear cell RCC and partly rhabdoid RCC; patient 6 a partly clear cell RCC and partly papillary dedifferentiated tumor; and patient 8 a partly clear cell RCC with sarcomatoid dedifferentiated tumor. Patient 10 did not have clear cell RCC but a tumor of the chromophobe subtype.

View this table:
  • View inline
  • View popup
TABLE 1

Patient Characteristics

In the control group (3 women and 2 men; median age, 62.2 y; range, 57.1–69.7 y), histopathologic examination revealed RCC in all patients. Of these patients, patient 11, 13, and 14 had the clear cell RCC subtype. The surgical specimen of patient 12 showed clear cell RCC, but a part was rhabdoid-dedifferentiated. The specimen of patient 15 revealed a type 2 papillary RCC (Table 1).

Treatment with sorafenib was generally well tolerated. Reported side effects were grade 3 skin toxicity according to the Common Terminology Criteria for Adverse Events (version 3; National Cancer Institute) in 2 patients, grade 2 diarrhea in 1 patient, and grade 2 stomatitis in 2 patients. No dose reductions or interruptions were necessary.

Scintigraphy

In all patients with later-proven clear cell RCC, the renal tumors before neoadjuvant treatment were readily visualized with 111In-girentuximab. The results of the quantitative analysis are summarized in Table 1. Imaging of the 1-cm-thick slices of the resected tumorous tissue, followed by histologic analysis, revealed that 111In-girentuximab accumulated in areas of vital tumor tissue whereas normal kidney and necrotic or non–clear cell RCC parts showed much lower uptake. In one patient, the lung metastases as observed on CT were also visualized with scintigraphy (patient 8, Fig. 2). In this patient, the uptake in the largest metastasis decreased by 74.8% after 4 wk of sorafenib treatment. Patients 7 and 9 were diagnosed with bilateral renal masses and had girentuximab uptake in both lesions before treatment (patient 9, shown in Fig. 3). Histologic analysis of the surgical specimens revealed that all these lesions were of the clear cell type (Table 1).

FIGURE 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2.

Anterior planar images of patient 8 with renal mass and lung metastases at baseline (A) and after 4 wk of sorafenib treatment (B). Clear targeting is seen of 111In-girentuximab in renal mass on left side and lung metastases at baseline (arrows). Decreased targeting is observed after 4 wk of sorafenib treatment.

FIGURE 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 3.

Posterior planar images of patient 9 with bilateral renal mass at baseline (A) and after 4 wk of sorafenib treatment (B). Clear targeting of 111In-girentuximab is seen in both lesions at baseline (arrows). Decreased targeting is observed after 4 wk of sorafenib treatment.

The mean 111In-girentuximab uptake in clear cell RCC renal tumors before sorafenib treatment was 0.013 %ID/g (range, 0.002–0.025 %ID/g). After 1 wk of sorafenib treatment, the mean uptake decreased to 0.008 %ID/g (range, 0.002–0.02 %ID/g), indicating a mean change of −14.4% (range, +9.1% to −47.1%, P = 0.225). After 4 wk of sorafenib treatment, the mean uptake decreased to 0.004 %ID/g (range, 0.002–0.01 %ID/g), which is equivalent to a mean change of −58.3% (range, −39.9% to −79.4%, P = 0.028) based on 6 lesions in 4 patients.

The tumors of all 5 patients who served as controls showed accumulation of 111In-girentuximab, with a mean uptake of 0.018 %ID/g. Uptake of 111In-girentuximab was also found in the papillary RCC in patient 15, albeit relatively low compared with the mean baseline uptake in the clear cell RCC tumors (0.003 %ID/g vs. a mean of 0.018 %ID/g).

Immunohistochemical Analysis

The results of the immunohistochemical analyses of the viable parts of the tumors are presented in Table 1. All clear cell RCC tumor specimens expressed CAIX (Table 1). Very low CAIX expression was also found in a vital tumor region of the surgical specimen of the papillary subtype from patient 15 (not shown).

Representative examples of postnephrectomy tumor specimens of each of the 3 groups are shown in Figure 4. From each tumor, multiple tumor blocks with the highest 111In uptake per gram of tissue (as determined in a γ counter) were used. High expression of CD31 was found in all tumors in the control group. As expected, sorafenib treatment induced a marked reduction of vessel density, as observed by CD31 immunohistochemistry. This effect was more pronounced in the group that was treated for 4 wk than in the group that was treated for 1 wk, suggesting that the decrease in vessel density was related to the duration of treatment.

FIGURE 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 4.

Immunohistochemical analyses of vital tumor specimens from different groups (magnification, ×20). Neoadjuvant treatment with sorafenib resulted in enhanced necrosis (hematoxylin and eosin) and decreased vessel density (CD31) but had no effect on CAIX expression.

DISCUSSION

This study confirmed previous studies showing that clear cell RCC lesions can be visualized with 111In-girentuximab imaging (17,19). High and specific uptake was seen in tumor lesions in all patients with clear cell RCC. Most importantly, we found that accumulation of girentuximab in clear cell RCC lesions was markedly reduced after sorafenib treatment in most patients.

The effect of sorafenib on girentuximab uptake was more pronounced in patients who were treated with sorafenib for 4 wk than in the group treated for 1 wk (−58.3% vs. −14.4%). All clear cell RCC tumor specimens in the current study were positive for CAIX, and we found no decrease in CAIX expression after the TKI treatment, indicating that sorafenib treatment did not down-regulate CAIX expression. We did observe decreased vessel densities in the sorafenib-treated groups when compared with the untreated group, making it highly likely that the reduced vessel density in the treated tumors results in poor perfusion and decreased uptake of 111In-girentuximab. The decrease in vessel density was most prominent after 4 wk of treatment (Table 1; Fig. 4). These results are in concordance with previous work of our group showing a similar effect of sorafenib on bevacizumab uptake (20) and with preclinical studies with other antibodies (21,22). Alternatively, the reduced 111In-girentuximab uptake could also be due to vascular normalization after sorafenib treatment (23). Vascular normalization may have led to decreased vessel permeability, which could also have led to reduced accumulation of the antibody in the tumor. We also found CAIX expression in a patient presenting with a papillary RCC subtype (patient 15). Although CAIX expression has been reported in papillary RCC subtypes, the expression is much lower than in clear cell RCC, in terms of both incidence and level of expression (8,24). Strikingly, the CAIX expression in this particular patient was found in a vital tumor region within a necrotic part of the surgical specimen (Supplemental Fig. 1, available at http://jnm.snmjournals.org), suggesting that this particular expression pattern is hypoxia-driven (25).

The TKI-induced decrease of antibody uptake in the clear cell RCC lesions has major implications for future therapeutic regimens combining both TKIs and antibody-based treatments (either cold or radiolabeled). The results of the present study indicate that antibody-mediated treatment should preferably be given before TKI treatment. Alternatively, the antibody could be administered after TKI treatment has been stopped. The interval required between TKI cessation and antibody treatment still needs to be determined in future studies. In addition, the diagnostic performance of radiolabeled antibodies (immuno-PET or immuno-SPECT) may similarly be affected by TKI treatment. Currently, a clinical trial is ongoing that focuses on the potential of 124I-girentuximab immuno-PET to detect early treatment response to sunitinib (26). It will be interesting to see whether this study also indicates that TKIs interfere with the uptake of girentuximab and whether it is possible to evaluate the response to TKI treatment with girentuximab-based imaging.

There are some limitations to our study. First, there was a 3-d interval between the discontinuation of the sorafenib treatment and the (partial) nephrectomy. Therefore, the immunohistochemical findings may not fully reflect the actual effect caused by sorafenib, though significant histologic changes in this short interval are unlikely.

Second, no biopsies of the renal lesions were taken at baseline, and therefore no intrapatient comparison of pre- and posttreatment tissue samples could be performed. In addition, vascular density may vary largely within and between RCC tumors. However, the CD31 expression in the samples from all patients treated with sorafenib for 4 wk was lower than in the other samples, suggesting that the lower vessel density is a direct effect of the treatment. Although the changes in CD31 expression after sorafenib treatment were evident (Fig. 4), microvessel densities in the treated groups could not be reliably quantified. In desmoplastic areas of treated tumors, we often observed cytoplasmic CD31 expression in nonendothelial cells. This phenomenon has been documented before and has been linked to the phenomenon of vasculogenic mimicry (27,28). Third, the current trial was not designed to assess the duration of the sorafenib-induced decreased antibody uptake. It remains to be investigated for how long antibody targeting to the tumor remains at lower levels after cessation of sorafenib treatment. Data on this subject are limited. There are animal data suggesting increased antibody uptake after discontinuation of sunitinib treatment (21,22), presumably due to rapid rebound vascularization. To date, no human data are available yet. Enhanced uptake of girentuximab shortly after discontinuation of TKI treatment is an interesting feature for further investigation because it could be an important step in the development of successful radioimmunotherapy strategies for clear cell RCC.

CONCLUSION

This study confirmed that clear cell RCC lesions can be identified with 111In-girentuximab scintigraphy. Moreover, we demonstrated that treatment with sorafenib markedly reduces the targeting of 111In-girentuximab in clear cell RCC lesions, suggesting that the effect of antibody-mediated treatment modalities would be profoundly hampered when directly combined with TKI treatment. Further research to evaluate the duration of this effect after discontinuation of TKI treatment is needed.

DISCLOSURE

The costs of publication of this article were defrayed in part by the payment of page charges. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734. Peter F.A. Mulders, Wim J.G. Oyen, Otto C. Boerman, and Egbert Oosterwijk serve or have served on an advisory board for Wilex AG, Munich, Germany. Sorafenib was provided by Bayer. Girentuximab was provided by Wilex. No other potential conflict of interest relevant to this article was reported.

Acknowledgments

We thank Maichel van Riel and Miranda van de Veerdonk for their help with the labeling of the antibody.

Footnotes

  • Published online Jan. 6, 2014.

  • © 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

REFERENCES

  1. 1.↵
    1. Motzer RJ,
    2. Hutson TE,
    3. Tomczak P,
    4. et al
    . Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–124.
    OpenUrlCrossRefPubMed
  2. 2.
    1. Escudier B,
    2. Eisen T,
    3. Stadler WM,
    4. et al
    . Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–134.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Sternberg CN,
    2. Davis ID,
    3. Mardiak J,
    4. et al
    . Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28:1061–1068.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Hartmann JT,
    2. Haap M,
    3. Kopp HG,
    4. Lipp HP
    . Tyrosine kinase inhibitors: a review on pharmacology, metabolism and side effects. Curr Drug Metab. 2009;10:470–481.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Desar IM,
    2. Mulder SF,
    3. Stillebroer AB,
    4. et al
    . The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients—a report of three cases. Acta Oncol. 2009;48:927–931.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Oosterwijk E,
    2. Ruiter DJ,
    3. Hoedemaeker PJ,
    4. et al
    . Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer. 1986;38:489–494.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Bui MH,
    2. Seligson D,
    3. Han KR,
    4. et al
    . Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003;9:802–811.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Leibovich BC,
    2. Sheinin Y,
    3. Lohse CM,
    4. et al
    . Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol. 2007;25:4757–4764.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Divgi CR,
    2. Bander NH,
    3. Scott AM,
    4. et al
    . Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res. 1998;4:2729–2739.
    OpenUrlAbstract
  10. 10.
    1. Steffens MG,
    2. Boerman OC,
    3. de Mulder PH,
    4. et al
    . Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res. 1999;5(suppl)3268s–3274s.
    OpenUrlAbstract/FREE Full Text
  11. 11.
    1. Divgi CR,
    2. O’Donoghue JA,
    3. Welt S,
    4. et al
    . Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer. J Nucl Med. 2004;45:1412–1421.
    OpenUrlAbstract/FREE Full Text
  12. 12.
    1. Brouwers AH,
    2. Buijs WC,
    3. Mulders PF,
    4. et al
    . Radioimmunotherapy with [131I]cG250 in patients with metastasized renal cell cancer: dosimetric analysis and immunologic response. Clin Cancer Res. 2005;11(suppl):7178s–7186s.
    OpenUrlAbstract/FREE Full Text
  13. 13.
    1. Brouwers AH,
    2. Mulders PF,
    3. de Mulder PH,
    4. et al
    . Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma. J Clin Oncol. 2005;23:6540–6548.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Brouwers AH,
    2. van Eerd JE,
    3. Frielink C,
    4. et al
    . Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re. J Nucl Med. 2004;45:327–337.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Stillebroer AB,
    2. Boerman OC,
    3. Desar IM,
    4. et al
    . Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. Eur Urol. 2013;64:478–485.
    OpenUrlCrossRefPubMed
  16. 16.↵
    A randomized, double blind phase III study to evaluate adjuvant cG250 treatment versus placebo in patients with clear cell RCC and high risk of recurrence (ARISER). ClinicalTrials.gov Web site. http://www.clinicaltrials.gov/ct2/show/NCT00087022. Published July 8, 2004. Updated May 21, 2013. Accessed December 11, 2013.
  17. 17.↵
    1. Brouwers AH,
    2. Buijs WC,
    3. Oosterwijk E,
    4. et al
    . Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with 131I or 111In: an intrapatient comparison. Clin Cancer Res. 2003;9(suppl):3953S–3960S.
    OpenUrlPubMed
  18. 18.↵
    1. Visser E,
    2. Postema E,
    3. Boerman O,
    4. Visschers J,
    5. Oyen W,
    6. Corstens F
    . Software package for integrated data processing for internal dose assessment in nuclear medicine (SPRIND). Eur J Nucl Med Mol Imaging. 2007;34:413–421.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Muselaers CH,
    2. Boerman OC,
    3. Oosterwijk E,
    4. Langenhuijsen JF,
    5. Oyen WJ,
    6. Mulders PF
    . Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma. Eur Urol. 2013;63:1101–1106.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Desar IM,
    2. Stillebroer AB,
    3. Oosterwijk E,
    4. et al
    . 111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib. J Nucl Med. 2010;51:1707–1715.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Nagengast WB,
    2. Lub-de Hooge MN,
    3. Oosting SF,
    4. et al
    . VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment. Cancer Res. 2011;71:143–153.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Oosterwijk-Wakka JC,
    2. Kats-Ugurlu G,
    3. Leenders WP,
    4. et al
    . Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IX-specific chimeric monoclonal antibody cG250. BJU Int. 2011;107:118–125.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Jain RK
    . Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58–62.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Ross H,
    2. Martignoni G,
    3. Argani P
    . Renal cell carcinoma with clear cell and papillary features. Arch Pathol Lab Med. 2012;136:391–399.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Russell J,
    2. Carlin S,
    3. Burke SA,
    4. Wen B,
    5. Yang KM,
    6. Ling CC
    . Immunohistochemical detection of changes in tumor hypoxia. Int J Radiat Oncol Biol Phys. 2009;73:1177–1186.
    OpenUrlCrossRefPubMed
  26. 26.↵
    Evaluate the utility of 124I-cG250 for the early detection of response to sunitinib in patients with metastatic renal cell carcinoma. ClinicalTrials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT01582204. Published April 18, 2012. Updated June 25, 2013. Accessed December 11, 2013.
  27. 27.↵
    1. Francescone R,
    2. Scully S,
    3. Bentley B,
    4. et al
    . Glioblastoma-derived tumor cells induce vasculogenic mimicry through Flk-1 protein activation. J Biol Chem. 2012;287:24821–24831.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Scully S,
    2. Francescone R,
    3. Faibish M,
    4. et al
    . Transdifferentiation of glioblastoma stem-like cells into mural cells drives vasculogenic mimicry in glioblastomas. J Neurosci. 2012;32:12950–12960.
    OpenUrlAbstract/FREE Full Text
  • Received for publication August 19, 2013.
  • Accepted for publication September 26, 2013.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 55 (2)
Journal of Nuclear Medicine
Vol. 55, Issue 2
February 1, 2014
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Tyrosine Kinase Inhibitor Sorafenib Decreases 111In-Girentuximab Uptake in Patients with Clear Cell Renal Cell Carcinoma
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Tyrosine Kinase Inhibitor Sorafenib Decreases 111In-Girentuximab Uptake in Patients with Clear Cell Renal Cell Carcinoma
Constantijn H.J. Muselaers, Alexander B. Stillebroer, Ingrid M.E. Desar, Marye J. Boers-Sonderen, Carla M.L. van Herpen, Mirjam C.A. de Weijert, Johan F. Langenhuijsen, Egbert Oosterwijk, William P.J. Leenders, Otto C. Boerman, Peter F.A. Mulders, Wim J.G. Oyen
Journal of Nuclear Medicine Feb 2014, 55 (2) 242-247; DOI: 10.2967/jnumed.113.131110

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Tyrosine Kinase Inhibitor Sorafenib Decreases 111In-Girentuximab Uptake in Patients with Clear Cell Renal Cell Carcinoma
Constantijn H.J. Muselaers, Alexander B. Stillebroer, Ingrid M.E. Desar, Marye J. Boers-Sonderen, Carla M.L. van Herpen, Mirjam C.A. de Weijert, Johan F. Langenhuijsen, Egbert Oosterwijk, William P.J. Leenders, Otto C. Boerman, Peter F.A. Mulders, Wim J.G. Oyen
Journal of Nuclear Medicine Feb 2014, 55 (2) 242-247; DOI: 10.2967/jnumed.113.131110
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Preclinical Development of CD38-Targeted [89Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma
  • Evaluation of Nonpeptidic Ligand Conjugates for the Treatment of Hypoxic and Carbonic Anhydrase IX-Expressing Cancers
  • Google Scholar

More in this TOC Section

  • Feasibility of Ultra-Low-Activity 18F-FDG PET/CT Imaging Using a Long–Axial-Field-of-View PET/CT System
  • Cardiac Presynaptic Sympathetic Nervous Function Evaluated by Cardiac PET in Patients with Chronotropic Incompetence Without Heart Failure
  • Validation and Evaluation of a Vendor-Provided Head Motion Correction Algorithm on the uMI Panorama PET/CT System
Show more Clinical Investigations

Similar Articles

Keywords

  • CAIX
  • girentuximab
  • imaging
  • renal cell carcinoma
  • tyrosine kinase inhibitor
SNMMI

© 2025 SNMMI

Powered by HighWire